Ondansetron-related hemorrhagic posterior reversible encephalopathy syndrome (PRES) following gastric bypass
Open Access
- 6 January 2016
- journal article
- research article
- Published by Springer Nature in SpringerPlus
- Vol. 5 (1) , 1-5
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome formally recognized in 1996, which describes specific changes noted on neuroimaging thought to be related to impaired cerebral blood flow autoregulation and endothelial dysfunction. We report a case of PRES in the setting of increased ingestion of ondansetron; complicated by hemorrhagic transformation and refractory intracranial hypertension. We hypothesize an association of 5-HT3 antagonism and PRES. This is a case study report; with review of previously published literature through PubMed search. We describe the case of a 25 year old man following bariatric surgery who increased his ingestion of ondansetron, taking up to 40 tablets/day due to excessive nausea and vomiting. The patient was hospitalized for progressively more severe headache of 1 week’s duration. Computed tomography (CT) revealed bilateral cerebral edema in the parietal and occipital lobes in the setting of elevated blood pressure (BP). Three days into his admission, following improvement in his BP with oral anti-hypertensive but continued use of the ondansetron, the patient developed near complete blindness. CT head imaging revealed progression of the posterior cerebral edema and intraparenchymal hemorrhage. He was admitted to our ICU and despite supportive treatment, his neurological examination worsened while CT head imaging findings remained stable. Invasive multimodality monitoring revealed elevated intracranial pressure. The patient was aggressively treated and after a prolonged hospitalization and rehabilitation course, made a significant recovery. This case highlights a very rare potential neurological complication of ondansetron, a commonly used medication. We hypothesize an underlying association between PRES and 5-HT3 antagonism, via the latter’s potential role in endothelial dysfunction. Prompt recognition and treatment of PRES is essential, in order to prevent secondary cerebral injury and the associated potentially grave consequences.Keywords
This publication has 24 references indexed in Scilit:
- Can clinical and MRI findings predict the prognosis of variant and classical type of posterior reversible encephalopathy syndrome (PRES)?Acta Radiologica, 2013
- Fatal atypical reversible posterior leukoencephalopathy syndrome: a case reportJournal of Medical Case Reports, 2013
- Hemorrhage in Posterior Reversible Encephalopathy Syndrome: Imaging and Clinical FeaturesAmerican Journal of Neuroradiology, 2009
- Reversible Posterior Leukoencephalopathy Syndrome and BevacizumabNew England Journal of Medicine, 2006
- Reversible posterior leukoencephalopathy syndrome: a misnomer reviewedInternal Medicine Journal, 2005
- Posterior Reversible Encephalopathy Syndrome: Prognostic Utility of Quantitative Diffusion-Weighted MR Images2002
- Nervous system distribution of the serotonin 5-HT3 receptor mRNA.Proceedings of the National Academy of Sciences, 1993
- Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases.American Journal of Roentgenology, 1992
- Hypertensive EncephalopathyArchives of Neurology, 1988
- Autonomic nerves, mast cells, and amine receptors in human brain vessels. A histochemical and pharmacological studyBrain Research, 1976